Pharmacogenomics pilot program; established, report.
Summary
HB2367 directs the Department of Human Resource Management, working with the Department of Health, to create a two-year pharmacogenomics pilot program for state employees. The program would offer genetic testing, analysis of results, and any needed follow-up appointments for up to 1,000 participating employees who are taking five or more prescriptions at the same time and who volunteer for the program.
The pilot must be developed and implemented by January 1, 2026, and it would expire on January 1, 2028. The bill also requires annual reporting to the chairs of the House Committee on Health and Human Services and the Senate Committee on Education and Health, and it authorizes the Department to adopt regulations needed to carry out the program.
Impact
The bill would create a new temporary state employee health initiative within Virginia government, requiring coordination between the Department of Human Resource Management and the Department of Health. It does not amend a specific existing statute in the text provided, but it would authorize the agencies to establish procedures, provide genetic testing services, and issue regulations for implementation, while also imposing reporting obligations to legislative committees.
Sentiment
The available voting history suggests limited opposition at the subcommittee level, with an 8-0 recommendation to lay the bill on the table. Because there are no committee transcripts provided, there is little direct evidence of debate, but the vote indicates the measure did not face recorded dissent in that setting. Overall, the bill appears to have been treated as a specialized pilot proposal rather than a broadly controversial measure.
Contention
The main potential points of contention are likely to be privacy, cost, and the use of genetic testing in an employer-sponsored program, especially for state employees. Questions may also arise about eligibility limits, since the program is restricted to employees taking five or more prescriptions and capped at 1,000 participants. No specific objections are recorded in the provided materials, but these issues would be the most likely areas of concern for lawmakers or stakeholders.